Valuation: GENFIT

Market Cap 47Cr 52Cr 44Cr 39Cr 75Cr 5.05TCr 75Cr 522.96Cr 203.4Cr 2.58TCr 196.75Cr 192.53Cr 8.29TCr P/E 2026 *
10.8x
P/E 2027 * 99.4x
Enterprise Value 33Cr 37Cr 30Cr 28Cr 52Cr 3.53TCr 53Cr 365.76Cr 142.26Cr 1.8TCr 137.6Cr 134.65Cr 5.8TCr EV / Sales 2026 *
3x
EV / Sales 2027 * 3.06x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-2.47%
1 week-8.57%
Current month-8.57%
1 month-33.21%
3 months-32.62%
6 months+21.74%
Current year+72.27%
1 week 8.82
Extreme 8.82
9.91
1 month 8.66
Extreme 8.66
14.5
Current year 5.05
Extreme 5.05
15.48
1 year 3.4
Extreme 3.4
15.48
3 years 2.62
Extreme 2.62
15.48
5 years 2.62
Extreme 2.62
15.48
10 years 2.62
Extreme 2.62
35.65
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Date Insider Type Main position Quantity % Market Cap. Importance
05/03/26 Exercice

Chief Operating Officer

11,250 0.0225%
05/03/26 Exercice

Chief Operating Officer

7,083 0.0142%
05/03/26 Sell

Chief Operating Officer

7,083 0.0142%
Change 5-day change 1-year change 3-year change Capi.($)
-2.37%-8.57%+164.74%+201.83% 52Cr
+4.16%+4.16%+49.37%+94.17% 7.47TCr
-1.08%-2.50%+21.59%+76.79% 5.88TCr
+0.28%+0.24%+6.74%+34.41% 4.84TCr
-3.76%-2.25%+329.09%+698.20% 4.28TCr
-2.30%-3.35%+26.81%+30.88% 4.28TCr
+0.31%-0.68%+5.30%+108.64% 4.12TCr
-0.11%+1.96%+9.19%+52.66% 3.11TCr
-2.07%+1.16%+35.00%+26.28% 3.03TCr
-1.96%-2.88%-8.97%-13.92% 2.4TCr
Average -0.91%-0.42%+63.89%+130.99% 3.95TCr
Weighted average by Cap. -0.26%-0.54%+55.63%+129.52%

Financials

2026 *2027 *
Net sales 11Cr 12Cr 10Cr 9.2Cr 17Cr 1.18TCr 18Cr 121.96Cr 47Cr 601.13Cr 46Cr 45Cr 1.93TCr 13Cr 15Cr 12Cr 11Cr 21Cr 1.41TCr 21Cr 145.97Cr 57Cr 719.48Cr 55Cr 54Cr 2.31TCr
Net income 4.27Cr 4.81Cr 4Cr 3.62Cr 6.84Cr 463.83Cr 6.89Cr 48Cr 19Cr 236.62Cr 18Cr 18Cr 760.67Cr 1.04Cr 1.17Cr 97.01L 87.93L 1.66Cr 112.58Cr 1.67Cr 12Cr 4.53Cr 57Cr 4.38Cr 4.29Cr 184.62Cr
Net Debt -14Cr -16Cr -13Cr -12Cr -22Cr -1.52TCr -23Cr -157.21Cr -61Cr -774.85Cr -59Cr -58Cr -2.49TCr -6.76Cr -7.61Cr -6.32Cr -5.73Cr -11Cr -733.64Cr -11Cr -76Cr -30Cr -374.26Cr -29Cr -28Cr -1.2TCr
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
07/26/07 €9.080 -2.37% 1,13,539
06/26/06 €9.300 +0.76% 2,65,341
05/26/05 €9.230 +1.43% 3,61,176
02/26/02 €9.100 -3.60% 2,87,895
01/26/01 €9.440 -4.84% 4,02,120
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.300EUR
Average target price
17.48EUR
Spread / Average Target
+87.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT
  1. Stock Market
  2. Stocks
  3. GNFT Stock